https://innovivaspecialtytherapeutics.com/innoviva-launches-innoviva-specialty-therapeutics-to-deliver-differentiated-therapies-in-areas-of-high-unmet-need-in-critical-care-and-infectious-disease/2025-04-28T08:29:30-07:00https://innovivaspecialtytherapeutics.com/results-from-pivotal-phase-3-attack-trial-of-investigational-sulbactam-durlobactam-for-treatment-of-serious-infections-caused-by-acinetobacter-published-in-the-lancet-infectious-diseases/2025-04-28T08:29:34-07:00https://innovivaspecialtytherapeutics.com/241-2/2025-04-28T08:28:53-07:00https://innovivaspecialtytherapeutics.com/gardp-and-innoviva-specialty-therapeutics-announce-completion-of-patient-recruitment-for-registrational-phase-3-gonorrhea-treatment-trial/2025-04-28T08:28:49-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-appoints-david-altarac-md-as-chief-medical-officer/2025-04-28T08:29:16-07:00https://innovivaspecialtytherapeutics.com/matt-ronsheim-appointed-president-of-innoviva-specialty-therapeutics/2025-04-28T08:29:13-07:00https://innovivaspecialtytherapeutics.com/xacduro-the-first-and-only-antibiotic-developed-to-target-acinetobacter-now-available-to-treat-hospital-acquired-bacterial-pneumonia-habp-and-ventilator-associated-bacterial-pneumonia-vabp-in-ad/2025-04-28T08:28:58-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-presents-new-data-on-its-critical-care-antibiotic-therapy-portfolio-at-infectious-disease-week-idweek-2023/2025-04-28T08:29:02-07:00https://innovivaspecialtytherapeutics.com/positive-results-announced-in-largest-pivotal-phase-3-trial-of-a-first-in-class-oral-antibiotic-to-treat-uncomplicated-gonorrhea/2025-04-28T08:29:07-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-positive-phase-3-oral-zoliflodacin-data-for-the-treatment-of-uncomplicated-gonorrhea-announced-at-escmid-global-2024/2025-04-28T08:29:20-07:00https://innovivaspecialtytherapeutics.com/zai-lab-and-innoviva-specialty-therapeutics-announce-nmpa-approval-for-xacduro-sulbactam-durlobactam-or-sul-dur-for-hospital-acquired-and-ventilator-associated-pneumonia-caused-by-acinetobacte/2025-04-28T08:29:23-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-inc-appoints-patricia-drake-as-chief-commercial-officer/2025-04-28T08:29:40-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-pathogen-targeted-antibiotic-xacduro-is-nominated-for-the-2024-prix-galien-usa-best-biotechnology-product-award/2025-04-28T08:29:44-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-presents-findings-from-subgroup-analyses-of-zoliflodacin-in-uncomplicated-gonorrhea-at-the-2024-sexually-transmitted-infections-conference/2024-11-06T08:54:02-08:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-to-present-new-clinical-data-from-its-development-pipeline-and-broad-commercial-portfolio-at-idweek-2024/2025-04-24T08:06:53-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-inc-signs-exclusive-distribution-and-licensing-agreement-to-acquire-u-s-marketing-rights-for-zevtera-ceftobiprole/2024-12-16T04:01:55-08:00https://innovivaspecialtytherapeutics.com/zevtera-ceftobiprole-an-advanced-generation-cephalosporin-antibiotic-now-commercially-available-in-the-u-s-to-treat-three-types-of-bacterial-infections/2025-06-02T08:10:14-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-receives-fda-new-drug-application-acceptance-for-zoliflodacin-a-first-in-class-oral-antibiotic-for-uncomplicated-gonorrhea-in-adults/2025-06-10T08:04:16-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-antimicrobial-therapies-zevtera-and-xacduro-nominated-for-the-2025-prix-galien-usa-best-pharmaceutical-product-award/2025-08-15T08:08:51-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-to-deliver-six-presentations-from-its-infectious-diseases-and-critical-care-portfolio-at-idweek-2025/2025-10-07T07:58:38-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-announces-oral-presentation-featuring-new-analyses-from-the-zoliflodacin-pivotal-phase-3-trial-at-idweek-2025/2025-10-20T10:38:37-07:00https://innovivaspecialtytherapeutics.com/u-s-fda-approves-nuzolvence-zoliflodacin-a-first-in-class-single-dose-oral-antibiotic-for-the-treatment-of-uncomplicated-urogenital-gonorrhea-in-adults-and-adolescents/2025-12-15T08:01:19-08:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-announces-publication-in-the-lancet-of-positive-zoliflodacin-phase-3-data-for-the-treatment-of-uncomplicated-urogenital-gonorrhea/2025-12-15T08:01:15-08:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-earns-strong-performance-rating-in-access-to-medicine-foundations-2026-antimicrobial-resistance-benchmark-report/2026-03-10T07:58:25-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-announces-distribution-and-licensing-agreement-with-dr-reddys-for-xacduro-in-select-international-markets/2026-06-16T13:15:15-07:00https://innovivaspecialtytherapeutics.com/innoviva-specialty-therapeutics-antimicrobial-therapies-xacduro-zevtera-and-nuzolvence-designated-finalists-for-the-2026-prix-galien-usa-best-pharmaceutical-product-award/2026-08-11T13:23:06-07:00